TY - JOUR
T1 - A case of chronic myelogenous leukemia that developed fibrous pericarditis owing to nilotinib use
AU - Miura, Shogo
AU - Murase, Kazuyuki
AU - Sakurada, Akira
AU - Takada, Kohichi
AU - Iyama, Satoshi
AU - Sato, Tsutomu
AU - Sato, Yasushi
AU - Miyanishi, Koji
AU - Kobune, Masayoshi
AU - Muranaka, Atsuko
AU - Tachibana, Kazutoshi
AU - Kato, Junji
PY - 2017/6
Y1 - 2017/6
N2 - A 64-year-old man was diagnosed with chronic-phase chronic myelogenous leukemia (CML) in May 2009. He was treated with imatinib and achieved complete cytogenetic response (CCyR) in 2 months. After 4 months of treatment, he developed interstitial pneumonia and became intolerant to imatinib. He was then switched to nilotinib from October of the same year. In June 2013, he was diagnosed with drug-induced pericarditis resulting from nilotinib use, and thus, nilotinib was discontinued. Subsequently, he was followed up without specific treatment for CML. In January 2014, he was admitted to the Dept. of Cardiovascular, Renal and Metabolic Medicine at our hospital because of heart failure. After examinations of cardiac function, he was diagnosed with constrictive pericarditis. Therefore, pericardiolysis was performed by the Dept. of Cardiovascular Surgery at our hospital. Pathologic findings showed hyaline-like fibrous tissue proliferation in the pericardium, which was diagnosed as fibrous pericarditis induced by nilotinib. We report a case of chronic myelogenous leukemia that developed fibrous pericarditis owing to nilotinib use.
AB - A 64-year-old man was diagnosed with chronic-phase chronic myelogenous leukemia (CML) in May 2009. He was treated with imatinib and achieved complete cytogenetic response (CCyR) in 2 months. After 4 months of treatment, he developed interstitial pneumonia and became intolerant to imatinib. He was then switched to nilotinib from October of the same year. In June 2013, he was diagnosed with drug-induced pericarditis resulting from nilotinib use, and thus, nilotinib was discontinued. Subsequently, he was followed up without specific treatment for CML. In January 2014, he was admitted to the Dept. of Cardiovascular, Renal and Metabolic Medicine at our hospital because of heart failure. After examinations of cardiac function, he was diagnosed with constrictive pericarditis. Therefore, pericardiolysis was performed by the Dept. of Cardiovascular Surgery at our hospital. Pathologic findings showed hyaline-like fibrous tissue proliferation in the pericardium, which was diagnosed as fibrous pericarditis induced by nilotinib. We report a case of chronic myelogenous leukemia that developed fibrous pericarditis owing to nilotinib use.
KW - Chronic myelogenous leukemia
KW - Fibrous pericarditis
KW - Nilotinib
UR - http://www.scopus.com/inward/record.url?scp=85029460309&partnerID=8YFLogxK
M3 - 学術論文
C2 - 28698448
AN - SCOPUS:85029460309
SN - 0385-0684
VL - 44
SP - 529
EP - 531
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 6
ER -
